智通财经APP获悉，基石药业-B(02616)午后涨超8%，截至发稿，涨8.28%，报4.97港元，成交额5718.62万港元。
消息面上，基石药业公布，首次披露两款自主研发、针对自身免疫/炎症性疾病的双特异性抗体药物靶点，包括CS2013 (B细胞激活因子[BAFF]/ 增殖诱导配体[APRIL])，和CS2015 (OX40配体[OX40L]/ 胸腺基质淋巴细胞生成素[TSLP])。
公告称，该两款药物具备同类最佳/同类首创潜力，目前均处于临床前候选化合物(PCC)确认阶段，临床前研究数据将在相关国际学术会议上公布。此外，基石药业计划于2025年下半年启动新药临床试验申请(IND)准备工作。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.